Flurbiprofen cataplasm

Abstract

The invention discloses a flurbiprofen cataplasm, which consists of a backing layer, a medicament storage space and a protective layer, wherein the medicament storage space consists of the following components in percentage by weight: 0.2 to 0.5 percent of flurbiprofen serving as an active ingredient, 5 to 10 percent of an oil-phase component, 5 to 10 percent of partial neutralization sodium polyacrylate, 20 to 40 percent of a humectant, 0.5 to 1.5 percent of carbomer 980, 1.5 to 3 percent of CMC-Na (sodium carboxymethyl cellulose), 0.2 to 0.4 percent of dihydroxyaluminium aminoacetate, 0.1 to 0.3 percent of EDTA-2Na (disodium ethylene diamine tetraacetic acid, 0.5 to 0.7 percent of tween 80, 1 to 3 percent of a filler and the balance of water, wherein the oil-phase component is prepared from caprin, oleic acid and peregal A-20 in a mass ratio of 1:(0.2 to 0.3):(0.2 to 0.3), and the partial neutralization sodium polyacrylate, the humectant, the carbomer 980, the CMC-Na, the dihydroxyaluminium aminoacetate, the EDTA-2Na and the tween 80 form a water-phase component.

Description

technical field [0001] The invention relates to an external preparation of a non-steroidal anti-inflammatory drug, in particular to a cataplasm. Background technique [0002] The molecular formula of flurbiprofen (CAS: 51543-40-9, flurbiprofen) is as follows: [0003] [0004] Flurbiprofen is a fluorine-containing non-steroidal anti-inflammatory drug, mainly used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, traumatic pain and other pain. Flurbiprofen acts as an anti-inflammatory and analgesic by inhibiting the activity of prostaglandin synthase cyclooxygenase. Compared with oral administration, when used for pain caused by trauma and inflammation of joints, soft tissues, and muscles, the use of external preparations can reduce the side effects of oral administration and accelerate the onset of the drug. [0005] Cataplasm refers to a new type of transdermal dosage form in which drugs are dissolved or mixed in a water-soluble polymer ...

AI Technical Summary

Problems solved by technology

Chinese patent CN031164412 discloses a kind of flurbiprofen cataplasm, and discloses a plurality of prescriptions, after testing, we find that the specific prescriptions disclosed in this document all have the defects of slow transdermal absorption rate and uneven drug release rate , the advantages of fast onset of action and long duration of action of the cataplasm cannot be repeated

Images